Verastem (VSTM +0.2%) says a subject with platinum-resistant ovarian cancer realized a complete...


Verastem (VSTM +0.2%) says a subject with platinum-resistant ovarian cancer realized a complete response in an ongoing trial of a defactinib/ paclitaxel combo treatment. The patient's CA-125 level normalized after one cycle and "has remained at normal levels since," the company says. (PR)

Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs